Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by the absence of dystrophin, a sarcolemmal protein which links the cytoskeleton to the extracellular matrix by interacting with a large number of proteins. Heart failure is a classic complication of this disease. The authors review the pathogenesis and therapeutics of cardiac involvement in DMD.
Fayssoil
Abdallah
A
University of Medicine and Dentistry of New Jersey, Camden, NJ, USA. fayssoil2000@yahoo.fr
Nardi
Olivier
O
Orlikowski
David
D
Annane
Djillali
D
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002304:Cardiac Pacing, Artificial / Q000379:methods; D009202:Cardiomyopathies / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D004359:Drug Therapy, Combination; D016189:Dystrophin / Q000096:biosynthesis / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods; D006333:Heart Failure / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000150:complications / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D033581:Stem Cell Transplantation / Q000379:methods; D016277:Ventricular Function, Left / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D016189:Dystrophin